Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Osimertinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 19/20 | 0.95 |
| ▸ | MLNR | O43193 | 1/20 | 0.95 |
| ▸ | KDM1A | O60341 | 1/20 | 0.95 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.95 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.95 |
| ▸ | INSR | P06213 | 1/20 | 0.95 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.95 |
| ▸ | HTR1A | P08908 | 1/20 | 0.95 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.95 |
| ▸ | DRD2 | P14416 | 1/20 | 0.95 |
| ▸ | NQO2 | P16083 | 1/20 | 0.95 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.95 |
| ▸ | DRD1 | P21728 | 1/20 | 0.95 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.95 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.95 |
| ▸ | HTR2A | P28223 | 1/20 | 0.95 |
| ▸ | HTR2C | P28335 | 1/20 | 0.95 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.95 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.95 |
| ▸ | CCKAR | P32238 | 1/20 | 0.95 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Osimertinib SCHEMBL29375936 | 1.00 | EGFR (0.95) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Osimertinib SCHEMBL14661152 | 1.00 | EGFR (0.95) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Osimertinib SCHEMBL29378405 | 0.97 | EGFR (1.00) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Osimertinib SCHEMBL29350904 | 0.97 | EGFR (1.00) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Osimertinib SCHEMBL14660911 | 0.97 | EGFR (1.00) | EGFRMLNRKDM1AABCB11ERBB2 | |
| Osimertinib SCHEMBL31538395 | 0.95 | EGFR (0.88) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL29232069 | 0.94 | EGFR (0.83) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL30682157 | 0.93 | EGFR (0.95) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19337108 | 0.93 | EGFR (0.85) | EGFRMLNRKDM1AABCB11ERBB2 | |
| SCHEMBL19336957 | 0.93 | EGFR (0.92) | EGFRMLNRKDM1AABCB11ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2744 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735453-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4735445-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| EP-4698173-A1 | TREATMENT OF NON-SMALL CELL LUNG CANCER WITH A COMBINATION OF 3-AMINO-3-(1-METHYL-1H-IMIDAZOL-5-YL)-6-OXA-2(4,6)-QUINOLINA-1,4(1,3)-DIBENZENACYCLOHEXAPHANE-22,44-DICARBONITRILE AND AN EGFR-TKI | Kura Oncology, Inc. (US) | 2026-02-25 | — | — | EP | claimed |
| EP-4695260-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4692075-A1 | USE OF A MECHANICAL FORCE IN THE PROCESS OF PREPARATION OF OSIMERTINIB | Université de Montpellier (FR) | 2026-02-11 | — | — | EP | claimed |
| US-20250367201-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM INC (US) | 2025-12-04 | — | — | US | claimed |
| WO-2025238176-A1 | COMBINATIONS OF EGFR/ERB AND BET INHIBITORS FOR GASTRIC CANCER | GENOME RESEARCH LIMITED (GB) | 2025-11-20 | — | — | WO | claimed |
| US-12465608-B2 | Osimertinib for use in the treatment of non-small cell lung cancer | ASTRAZENECA AB (SE) | 2025-11-11 | — | — | US | claimed |
| US-20250325543-A1 | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL LUNG CANCER | ASTRAZENECA AB (SE) | 2025-10-23 | — | — | US | claimed |
| US-20220175783-A1 | OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER | ASTRAZENECA AB (SE) | 2022-06-09 | — | — | US | claimed |
| WO-2022093789-A1 | SMALL MOLECULE INHIBITORS OF APEX, ALONE AND IN COMBINATION WITH OTHER CANCER DRUGS TO INHIBIT GROWTH OF CANCER CELLS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | WO | claimed |
| WO-2022093919-A1 | INHIBITORS OF EXO1 IN COMBINATION WITH OTHER CANCER DRUGS TO INHIBIT CANCER CELLS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-05 | — | — | WO | claimed |
| WO-2022036024-A9 | METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| EP-3964217-A1 | USE OF COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT, DIMER OR TRIMER THEREOF IN PREPARATION OF DRUG FOR TREATING CANCER | Newish Technology (Beijing) Co., Ltd. (CN) | 2022-03-09 | — | — | EP | claimed |
| WO-2022046867-A1 | OSIMERTINIB AND SELPERCATINIB COMBINATIONS FOR THE TREATMENT OF EGFR- AND RET-ASSOCIATED CANCERS | LOXO ONCOLOGY, INC. (US) | 2022-03-03 | — | — | WO | claimed |
| WO-2022046947-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF A VARIANT | GUARDANT HEALTH, INC. (US) | 2022-03-03 | — | — | WO | claimed |
| EP-3957310-A1 | COMPOSITION AND USE THEREOF IN PREPARATION OF MEDICATION FOR TREATING CANCER | Newish Technology (Beijing) Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| WO-2022036024-A2 | METHODS AND COMPOSITIONS FOR STIMULATING GAMMA DELTA T CELLS | UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) | 2022-02-17 | — | — | WO | claimed |
| EP-3946346-A1 | OSIMERTINIB FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER | Astrazeneca AB (SE) | 2022-02-09 | — | — | EP | claimed |